1. Home
  2. ELDN vs IPSC Comparison

ELDN vs IPSC Comparison

Compare ELDN & IPSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eledon Pharmaceuticals Inc.

ELDN

Eledon Pharmaceuticals Inc.

HOLD

Current Price

$1.97

Market Cap

219.4M

Sector

Health Care

ML Signal

HOLD

Logo Century Therapeutics Inc.

IPSC

Century Therapeutics Inc.

SELL

Current Price

$1.36

Market Cap

248.1M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
ELDN
IPSC
Founded
2004
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medicinal Chemicals and Botanical Products
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
219.4M
248.1M
IPO Year
2014
2021

Fundamental Metrics

Financial Performance
Metric
ELDN
IPSC
Price
$1.97
$1.36
Analyst Decision
Strong Buy
Buy
Analyst Count
6
5
Target Price
★ $9.00
$4.75
AVG Volume (30 Days)
918.4K
★ 938.1K
Earning Date
11-12-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
30.67
★ 91.30
EPS
N/A
★ N/A
Revenue
N/A
★ $109,164,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 1556.76
52 Week Low
$1.35
$0.46
52 Week High
$4.49
$2.97

Technical Indicators

Market Signals
Indicator
ELDN
IPSC
Relative Strength Index (RSI) 35.64 40.76
Support Level N/A $1.29
Resistance Level $3.14 $2.45
Average True Range (ATR) 0.27 0.18
MACD -0.07 -0.00
Stochastic Oscillator 3.83 3.67

Price Performance

Historical Comparison
ELDN
IPSC

About ELDN Eledon Pharmaceuticals Inc.

Eledon Pharmaceuticals Inc is a clinical stage biotechnology company using immunology expertise in targeting the CD40 Ligand pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis. Its compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40L, a well-validated biological target that has broad therapeutic potential. It operates as one reportable segment, focused on the development of tegoprubart, to develop therapies to protect transplanted organs and prevent rejection, and to treat ALS.

About IPSC Century Therapeutics Inc.

Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.

Share on Social Networks: